Hemogenyx Pharmaceuticals PLC (HEMO) - Net Assets

Latest as of June 2025: GBX-546.41K GBX ≈ $-66.48 USD

Based on the latest financial reports, Hemogenyx Pharmaceuticals PLC (HEMO) has net assets worth GBX-546.41K GBX (≈ $-66.48 USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX3.10 Million ≈ $377.33 USD) and total liabilities (GBX3.65 Million ≈ $443.82 USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check HEMO capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.

Key Net Assets Metrics

Metric Value
Current Net Assets GBX-546.41K
% of Total Assets -17.62%
Annual Growth Rate 30.48%
5-Year Change -2.53%
10-Year Change N/A
Growth Volatility 434.38

Hemogenyx Pharmaceuticals PLC - Net Assets Trend (2015–2024)

This chart illustrates how Hemogenyx Pharmaceuticals PLC's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see HEMO company net worth.

Annual Net Assets for Hemogenyx Pharmaceuticals PLC (2015–2024)

The table below shows the annual net assets of Hemogenyx Pharmaceuticals PLC from 2015 to 2024. Also explore HEMO net assets growth trend to track the company's year-over-year net asset growth rate.

Year Net Assets Change
2024-12-31 GBX853.49K
≈ $103.85		 -69.31%
2023-12-31 GBX2.78 Million
≈ $338.37		 -14.26%
2022-12-31 GBX3.24 Million
≈ $394.64		 -60.29%
2021-12-31 GBX8.17 Million
≈ $993.76		 +832.71%
2020-12-31 GBX875.68K
≈ $106.55		 +350.89%
2019-12-31 GBX-349.04K
≈ $-42.47		 -136.39%
2018-12-31 GBX959.17K
≈ $116.70		 -55.01%
2017-12-31 GBX2.13 Million
≈ $259.39		 +135.90%
2016-12-31 GBX903.71K
≈ $109.96		 +1061.28%
2015-12-31 GBX77.82K
≈ $9.47		 --

Equity Component Analysis

This analysis shows how different components contribute to Hemogenyx Pharmaceuticals PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 3557553900.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Common Stock GBX35.05K 3.90%
Other Comprehensive Income GBX1.07 Million 119.51%
Other Components GBX35.37 Million 3941.07%
Total Equity GBX897.51K 100.00%

Hemogenyx Pharmaceuticals PLC Competitors by Market Cap

The table below lists competitors of Hemogenyx Pharmaceuticals PLC ranked by their market capitalization.

Company Market Cap
International Zeolite Corp
V:IZ
 $306.77K
SkinBioTherapeutics PLC
LSE:SBTX
 $307.45K
Provexis plc
LSE:PXS
 $308.26K
GCL Global Holdings Ltd Warrants
NASDAQ:GCLWW
 $308.55K
SysGroup PLC
LSE:SYS
 $305.61K
SCRYB INC.
F:EIY
 $301.47K
Wag! Group Co.
NASDAQ:PET
 $299.36K
TUGA INNOVATIONS INC.
F:DQ5
 $297.55K

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Hemogenyx Pharmaceuticals PLC's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 2,818,729 to 897,514, a change of -1,921,215 (-68.2%).
  • Net loss of 5,619,181 reduced equity.
  • New share issuances of 3,712,490 increased equity.
  • Other comprehensive income increased equity by 6,143,370.
  • Other factors decreased equity by 6,157,894.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income GBX-5.62 Million -626.08%
Share Issuances GBX3.71 Million +413.64%
Other Comprehensive Income GBX6.14 Million +684.49%
Other Changes GBX-6.16 Million -686.11%
Total Change GBX- -68.16%

Book Value vs Market Value Analysis

This analysis compares Hemogenyx Pharmaceuticals PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1728.86x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 1743.83x to 1728.86x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2014-12-31 GBX0.27 GBX470.00 x
2015-02-28 GBX0.27 GBX470.00 x
2015-12-31 GBX0.48 GBX470.00 x
2016-12-31 GBX1.02 GBX470.00 x
2017-12-31 GBX3.28 GBX470.00 x
2018-12-31 GBX1.07 GBX470.00 x
2019-12-31 GBX-0.38 GBX470.00 x
2020-12-31 GBX0.86 GBX470.00 x
2021-12-31 GBX4.23 GBX470.00 x
2022-12-31 GBX1.34 GBX470.00 x
2023-12-31 GBX1.00 GBX470.00 x
2024-12-31 GBX0.27 GBX470.00 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Hemogenyx Pharmaceuticals PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -626.08%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 0.00%
  • • Asset Turnover: 0.00x
  • • Equity Multiplier: 4.69x
  • Recent ROE (-626.08%) is below the historical average (-155.36%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2014 -14.34% 0.00% 0.00x 1.00x GBX-10.64K
2015 -14.34% 0.00% 0.00x 1.00x GBX-10.64K
2015 -232.43% -2642.29% 0.02x 4.17x GBX-188.66K
2016 -57.53% 0.00% 0.00x 1.16x GBX-610.27K
2017 -110.78% 0.00% 0.00x 1.12x GBX-2.57 Million
2018 -154.04% 0.00% 0.00x 2.40x GBX-1.57 Million
2019 0.00% 0.00% 0.00x 0.00x GBX-1.42 Million
2020 -233.74% 0.00% 0.00x 2.99x GBX-2.17 Million
2021 -62.25% 0.00% 0.00x 1.04x GBX-5.92 Million
2022 -121.49% 0.00% 0.00x 2.17x GBX-4.31 Million
2023 -237.37% 0.00% 0.00x 2.17x GBX-6.97 Million
2024 -626.08% 0.00% 0.00x 4.69x GBX-5.71 Million

Industry Comparison

This section compares Hemogenyx Pharmaceuticals PLC's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $1,096,004
  • Average return on equity (ROE) among peers: -345.76%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Hemogenyx Pharmaceuticals PLC (HEMO) GBX-546.41K -14.34% N/A $306.59K
4BASEBIO UK SOCIETAS (4BB) $-492.00K 0.00% 0.00x $1.06 Million
Aptamer Group PLC (APTA) $304.00K -2577.63% 8.06x $106.65K
Arecor Therapeutics PLC (AREC) $6.45 Million 10.29% 0.26x $401.97K
Avacta Group PLC (AVCT) $14.00K -764.29% 1.36x $3.99 Million
BSF Enterprise Plc (BSFA) $2.72 Million -40.97% 0.11x $14.84K
Bioventix (BVXP) $-71.00K 0.00% 0.00x $985.36K
Cizzle Biotechnology Holdings PLC (CIZ) $1.67 Million -80.55% 0.34x $77.17K
CRISM Therapeutics Corporation (CRTX) $15.21 Million -4.50% 0.05x $93.94K
Fusion Antibodies PLC (FAB) $323.00K 0.00% 1.18x $154.88K
Faron Pharmaceuticals Oy (FARN) $-15.16 Million 0.00% 0.00x $485.05K

About Hemogenyx Pharmaceuticals PLC

LSE:HEMO UK Biotechnology
Market Cap
$306.59K
GBX2.52 Billion GBX
Market Cap Rank
#31232 Global
#992 in UK
Share Price
GBX470.00
Change (1 day)
+2.17%
52-Week Range
GBX412.50 - GBX1300.00
All Time High
GBX1545.00
Categories
Companies in UK Biotechnology
About

Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of treatments for blood cancer. The company's lead product candidate is the HG-CT-1 therapy for the treatment of relapsed or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat viral infections derived and for certain cancer and neurol… Read more